Tonix Pharmaceuticals Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Tonix Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tonix Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tonix Pharmaceuticals saw a drop in short interest in August. As of August 13th, there was short interest totaling 13,920,000 shares, a drop of 12.8% from the July 29th total of 15,960,000 shares. Based on an average daily trading volume, of 11,400,000 shares, the short-interest ratio is presently 1.2 days.
View Tonix Pharmaceuticals' Short Interest.

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Tonix Pharmaceuticals.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Sunday, August, 8th. The company reported ($0.07) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.07).
View Tonix Pharmaceuticals' earnings history.

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNXP shares have decreased by 29.1% and is now trading at $0.5890.
View which stocks have been most impacted by COVID-19.

Shares of Tonix Pharmaceuticals reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

1 brokerages have issued twelve-month target prices for Tonix Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $2.00 in the next year. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Tonix Pharmaceuticals include Zogenix (ZGNX), ADVANZ PHARMA (CXRXF), Praxis Precision Medicines (PRAX), Dyne Therapeutics (DYN), Annexon (ANNX), Kiniksa Pharmaceuticals (KNSA), Akero Therapeutics (AKRO), VBI Vaccines (VBIV), Crinetics Pharmaceuticals (CRNX), Shattuck Labs (STTK), BioXcel Therapeutics (BTAI), Gossamer Bio (GOSS), Celularity (CELU), Ocular Therapeutix (OCUL) and Cara Therapeutics (CARA).
View all of TNXP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Tonix Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.05%), Vanguard Group Inc. (4.41%), Renaissance Technologies LLC (2.01%), Geode Capital Management LLC (1.54%), State Street Corp (1.43%) and Northern Trust Corp (0.87%). Company insiders that own Tonix Pharmaceuticals stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends for Tonix Pharmaceuticals.

TNXP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Millennium Management LLC, Bridgeway Capital Management LLC, and First Trust Advisors LP.
View insider buying and selling activity for Tonix Pharmaceuticals or view top insider-selling stocks.

TNXP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Northern Trust Corp, Nuveen Asset Management LLC, Vanguard Group Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell, and Seth Lederman.
View insider buying and selling activity for Tonix Pharmaceuticals or or view top insider-buying stocks.

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNXP stock can currently be purchased for approximately $0.59.

Tonix Pharmaceuticals has a market capitalization of $210.58 million. The company earns $-50,460,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Tonix Pharmaceuticals employs 26 workers across the globe.

The official website for Tonix Pharmaceuticals is www.tonixpharma.com.

Tonix Pharmaceuticals is headquartered at 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022.

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at (212) 980-9155 or via email at [email protected].